Sentences with phrase «with islet cell»

For example, we're one of a handful of hospitals in the country to offer total pancreatectomy with islet cell autotransplantation (autologous islet cell transplantation), a procedure aimed at preventing diabetes or reducing its effects after removal of the pancreas due to pancreatitis.

Probably, these perturbations noted with islet cell functions could be a multifactorial effect and can be attributed to a reduced threshold of the beta - cells reported under MS [18] that can all be accelerated with the induction of AP by L - arginine.

Assessment of hASC - CM composition found high expression of various human growth factors (IL ‐ 6, 8, 12, eotaxin, IP10, MCP ‐ 1, VEGF, and TIMP ‐ 1) in the supernatant following the co-culture of hASCs with islet cells, while IP10, eotaxin, VEGF, and TIMP ‐ 1 became increased with time during islet co ‐ culture, suggesting the presence of paracrine cross ‐ talk between islets and hASCs.

Not exact matches

The article described how a team of researchers, surgeons and radiologists had successfully carried out a number of islet cell transplantations in people with Type 1 diabetes, in Edmonton, Canada..

Other mice, with robust beta cells that were good at repairing DNA damage, were able to stay non-diabetic for life, even when those islets were placed under severe cellular stress.

In addition to looking at mouse models of diabetes, the researchers also showed that exposure of human pancreatic islet cells — both from healthy donors and from patients with Type 1 diabetes — to fasting - mimicking diet in a dish stimulated insulin production.

Combining a new hydrogel material with a protein that boosts blood vessel growth could improve the success rate for transplanting insulin - producing islet cells into persons with type 1 diabetes.

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

The researchers also anticipate that their gene expression data and newly described islet - cell isolation technique, coupled with the ongoing tissue procurement effort, will be helpful to others studying pancreatic development and diabetes.

The results indicate that beta cell function does not decline with age, and instead suggest that islet function is threatened by an age - dependent impairment of vessels that support them with oxygen and nutrients,» says Per - Olof Berggren at the Rolf Luft Research Center for Diabetes and Endocrinology at Karolinska Institutet, who led the study together with Alejandro Caicedo at University of Miami Miller School of Medicine and Hong Gil Nam at DGIST in Republic of Korea.

Transplantation of pancreatic islets — cell clusters that contain insulin - producing cells — prevents severe, potentially life - threatening drops in blood sugar in people with type 1 diabetes, according to new research.

New clinical trial results show that transplantation of pancreatic islets — cell clusters that contain insulin - producing cells — prevents severe, potentially life - threatening drops in blood sugar in people with type 1 diabetes.

People with Type 2 diabetes have an excess of a protein called islet amyloid polypeptide, or IAPP, and the accumulation of this protein is linked to the loss of insulin - producing pancreatic beta cells.

To corroborate the findings, the researchers also developed a novel mouse model that was deficient for autophagy specifically in beta cells with expression of the human form of islet amyloid polypeptide.

In these two microscopy images, human islets (the source of insulin cells) were poisoned with a drug to remove the insulin cells, and then treated with either an empty virus (left panel) or the therapeutic virus (right panel), and then grown in a diabetic mouse.

Now the scientists have found increased frequencies of these cells in samples of children with recent onset of islet cell autoimmunity — an early stage of type 1 diabetes.

The results showed that Tg - hIAPP injected with pancreatic homogenate containing IAPP aggregates (the Tg / Tg group) exhibited an altered islet morphology characterized by the appearance of α - and δ - cells in the center of the islets, compared with the classical pattern in mice (observed in Tg / WT), in which these cells are mostly confined to the periphery of the islets (Brissova et al., 2005).

Dysfunction and loss of β cells has been associated with glucolipotoxicity (Poitout and Robertson, 2002; El - Assaad et al., 2003), islet cholesterol accumulation (Brunham et al., 2010), and islet inflammation (Donath and Shoelson, 2011).

Autopsy studies in humans suggest that islet amyloid is associated with the loss of β cells mass (Clark et al., 1988).

In the group of mice treated with synthetic IAPP aggregates, we observed a substantial reduction in the area of islets occupied by β cells as compared with controls untreated or treated with the same concentration of nonaggregated IAPP (Fig. 7 D).

The area of the islets occupied by β cells was significantly reduced in the Tg / Tg group, as compared with control mice.

After implantation, the cells are expected to mature into the full complement of islet cells, including insulin - producing beta cells, offering a potential functional cure for patients with high - risk type 1 diabetes.

In fact, while Islet cell autoantibodies, or IA, are considered a red flag for type 1 diabetes, not every child with IA will progress to full - blown disease, She says, although multiple autoantibodies definitely increase that risk.

Dr. Kulkarni's research focuses on investigating signaling pathways impacting growth and function of pancreatic islet cells with the long - term goal of improving therapeutic approaches for the treatment of type 1 and type 2 diabetes and obesity - associated conditions.

Moreover, all of the donated pancreases displayed active insulin - producing beta cells, with some of the cells scattered individually and others clumped with different kinds of hormone - producing cells in the normal pancreatic structures called islets.

Although cord blood stem cell transplant is becoming increasingly promising, the Clinical Islet Program is not currently involved with cord blood as a treatment for diabetes.

In addition, the molecular beacons technique http://www.lependart.com could have broad applications across regenerative medicine, because it could be used with other types of cells produced from stem cell cultures, such as brain cells or insulin - producing islet cells.

Complementing this work are recent advances at Joslin identifying new islet growth in patients with long - standing type 1 diabetes, as well as identifying potential islet growth factors, which occur in situations of insulin resistance, that could be used to stimulate the growth of the patient's own beta cells.

In addition to providing an unlimited supply of cells for implantation, the PEC - Direct approach has the potential to provide other advantages relative to cadaver islet transplants such as delivering a more consistent product preparation under quality - controlled cGMP conditions, with a more straightforward and safer mode of delivery.

If we could find therapies that detect complications at an early stage, people with diabetes could lead healthier, more productive lives,» says senior author Rohit Kulkarni, M.D., Ph.D., Principal Investigator in the Section on Islet Cell and Regenerative Biology at Joslin Diabetes Center and Associate Professor of Medicine at Harvard Medical School.

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.

The encapsulation of pancreatic islets within mainly alginate - based macro - or microcapsules with various physical configurations may allow protecting the islet graft without the need for immunosuppressive agents and moreover expanding the donor pool to animal tissue and novel insulin - producing cells.

Coating Human Pancreatic Islets With CD4 + CD25highCD127 - Regulatory T Cells as a Novel Approach for the Local Immunoprotection.

Inhibition of DPP - 4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

Exploitation of alternative cell sources (xenogeneic primary islets, stem cell derived beta cells) for utilization in our encapsulation device (collaboration with Anthony Gavalas, CRTD)

Our group is specifically working on improvement of islet isolation and transplantation protocols in clinical practice and the development of novel therapeutic options in the field of beta cell replacement with a clear translational «bench to bedside» approach by linking experimental research with preclinical and clinical work:

San Diego, CA (December 9, 2008)-- Novocell, Inc., a stem cell engineering company, today announced a collaboration with renowned stem cell researcher Dr. Shinya Yamanaka of Kyoto University, Japan, to allow Novocell to explore the creation of human islet cells from induced pluripotent stem (iPS) cells.

«I highly respect Novocell technologies and am pleased to collaborate with Novocell and explore the potential of their hES cell to islet cell advances in combination with our iPS cells as a potential new sources for the generation of cellular models and therapies for diabetes,» said Dr. Yamanaka, Director of Center for iPS Research and Application at Kyoto University.

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.

«These results suggest that, as a result of the FMD and re-feeding cycle, the pancreatic islets contain an elevated number of cells with features of progenitor cells, which may differentiate and generate insulin - producing cells,» noted the research.

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.

TIMP - 1, previously described as being able to protect against cytokine and STZ ‐ induced β cell death [5, 6], was one of the most enriched factors in co-culture experiments using mouse and human islet cells, and the authors found that TIMP - 1 was induced by pro-inflammatory factors which are commonly associated with T1DM.

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.

Creation of a rich subcutaneous vascular network with implanted adipose tissue - derived stromal cells and adipose tissue enhances subcutaneous grafting of islets in diabetic mice.

The PEC - Encap (also known as VC - 01) product candidate is designed to deliver stem cell - derived islet replacement therapies to patients with type 1 diabetes as well as patients with type 2 disease that require insulin.

The Emory Transplant Center has conducted clinical trials since 2003 transplanting human pancreatic islet cells into patients with Type I diabetes.

«JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC - Direct islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.

«The PEC - Direct islet cell replacement therapy is designed to help patients with the most urgent medical need.»